CVRX
CVRx, Inc.
CVRX trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over CVRX overall, supported by stronger fundamentals.
CVRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CVRX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CVRX PE Valuation
CVRX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CVRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CVRX's earnings, revenue and profitability to hold roughly steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CVRX on the outlook, with more favorable earnings and revenue expectations.
CVRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.00 | -$0.02 |
| Q2 2026 | -$1.97 | +$0.09 |
| Q1 2026 | -$2.01 | +$0.13 |
| Q4 2025 | -$2.04 | +$0.61 |
| Q3 2025 | -$1.98 | +$0.73 |
| Q2 2025 | -$2.06 | +$0.51 |
| Q1 2025 | -$2.14 | +$0.34 |
| Q4 2024 | -$2.65 | -$0.66 |
CVRX is still losing money, but less than at its worst: $2.00 per share over the past year, against $2.71 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CVRX on earnings quality, reporting a profit while its opponent remains loss making.
CVRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.8M | -5.8% |
| Q2 2026 | $15.7M | +16% |
| Q1 2026 | $14.8M | +20% |
| Q4 2025 | $16M | +4.4% |
| Q3 2025 | $14.7M | +9.8% |
| Q2 2025 | $13.6M | +15% |
| Q1 2025 | $12.3M | +15% |
| Q4 2024 | $15.3M | +36% |
CVRX's revenue is growing: $14M last quarter, down 5.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -94% | -11 points |
| Q2 2026 | -83% | +23 points |
| Q1 2026 | -82% | +27 points |
| Q4 2025 | -70% | -2.8 points |
| Q3 2025 | -84% | +14 points |
| Q2 2025 | -106% | +13 points |
| Q1 2025 | -109% | +98 points |
| Q4 2024 | -67% | +19 points |
CVRX's operating margin was −94% last quarter, down 11 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CVRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CVRX on profitability, with a higher operating margin.
CVRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11M | -$991K |
| Q2 2026 | -$8.9M | -$899K |
| Q1 2026 | -$12.3M | +$595K |
| Q4 2025 | -$9.8M | -$1.8M |
| Q3 2025 | -$10M | +$443K |
| Q2 2025 | -$8M | +$2.1M |
| Q1 2025 | -$12.9M | -$1.1M |
| Q4 2024 | -$8.1M | -$52K |
CVRX has burned cash in almost every quarter: −$42M over the past year, against −$39M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CVRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CVRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +731K shares |
| 1 year | +4.1% | +1.1M shares |
| 3 years | +31% | +6.4M shares |
| 5 years | +7343% | +26.9M shares |
CVRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CVRX Net Leverage
CVRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CVRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.1 | Oversold |
| Stochastic | 1.7 | Oversold |
CVRX's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CVRX PE vs Healthcare Sector
CVRX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CVRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.43 | 56% below |
| 20 week MA | $2.88 | 78% below |
| 50 week MA | $5.38 | 88% below |
| 100 week MA | $7.50 | 92% below |
| 200 week MA | $11.1 | 94% below |
CVRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CVRX on trend strength, trading above more of its moving averages.
CVRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.5 | $12.2 | -52% |
| 2022 | $12.2 | $16.7 | +37% |
| 2023 | $16.7 | $31.4 | +88% |
| 2024 | $31.4 | $13.2 | -58% |
| 2025 | $13.2 | $7.42 | -44% |
| 2026 YTD | $7.42 | $0.63 | -92% |
CVRX has finished lower in three of the last five years. It's down 92% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CVRX on returns for 2026, with the stronger performance.